Studies that used prolonged contrast media infusion in canine arteries have generated controversy regarding the arrhythmogenic potential of low osmoiarity, nonionio contrast agents. in order to establish the relative safety of these agents in the more typical setting of boius injections, 4 mll intracoronary btilus injections of Hypaqus76 (n = 54), iohexoi-350 (n = 51), and iohexoi-140 (n = 51) were given in random order to 10 anesthetized, open-chest dogs undergoing programmed cardiac stimuiation. Hemodynamics and electrocardiogram were monitored during stimulation, both during and for 2 minutes after the end qf contrast hifusion. Occurrence of evoked sfngie and coupled premature ventricular cur&actions and nonsustained ventricular tachyqardia did not d&fer statistically among agents. Sustained ventricular tachycardia (five episodes) and w~ntricuiar fibrillation (seven episodes) occurred only after Hypaqua76 injections @ < 0.002). Thase results differ from those in studies that use ctitinuous contrast infusiog and suggest that iow osmoiarity nonionic contrast agents are as safe as high osmolarity nonionic contrast media. Both appear safer than ionic contrast material. (AM ' HEART J 1969; 117:1263.) Many studies14 document the hemodynamic and electrocardiographic effecta of ionic and nonionic contrast agents, and report fewer adverse effects with nonionic contrast media. Hyperosmolarity has been implicated as a major determinapt of toxicity, but studies that used prolonged infusions of nonioqic isoosmolar agents have contested the safety of such agents with respect to induction of ventricular arrhythmia.7-10 The clinical relevance of such studies is questionable, however, since intracoronary contrast infusion for diagnostic and intervention purposes is usually performed with rapid bolus injections rather than with prolonged infusions. The present study compares the arrhythmogenicity of bolus injections of high and low osmolarity nonionic agents and ionic contrast media.
METHODS
Ten mongrel dogs (mean weight 21.9 kg) were anesthetized with 35 mg/kg of sodium pentobarbital and ventilated with a Harvard pump (15 ml/kg) (Harvard Apparatus Inc., S. Natick, Mass.). The left carotid artery and the left jugular vein were dissected for vascular access. A left thoracotomy was performed in the fifth intercostal space, the pericardium was incised, and the heart was exposed. Needle electrodes were inserted subcutaneously to monitor the electrocardiogram A 5F micromanometer (Millar Instruments, Inc., Houston, Texas) was inserted into the left ventricle, via apical puncture, to monitor left ventricular pressure and its first derivative (dP/dt).
Two leads were clipped onto the surface of the right atrium and two leads were sutured to the left ventricle. These leads were connected to a cardiac stimulator (Model DTU-110, Bloom Associates, Narberth, Pa.) for programmed pacing. All animals were pretreated with propranolol(l mg/kg) and atropine (1 mg) to reduce effects of sympathetic and parasympathetic tone on heart rate and function. Programmed stimulation consisted of atrial pacing followed by three ventricular extrastimuli. The atria1 pacing rate was selected at 5 to 10 beats faster than the intrinsic heart rate and a stable 1: 1 atrioventricular (AV) conduction was maintained. At the end of a four-beat train of atria1 pacing, diastole was scanned with a single extrastimulus (S,). The S, was started late in diastole and moved toward the basic drive train at 10 msec intervals until the S, repeatedly failed to stimulate the ventricle. The interval between the last QRS (S,) complex of the basic train and S, was defined as the ventricular effective refractory period (ERP) and S, was delivered 10 msec beyond it. A second extrastimulus (S,) interval followed SZ, and the initial coupling interval was equal to S,-S,. The S,-S, interval was reduced to 10 msec steps until S, failed to provoke a ventricular response. The S,-S, interval was defined as the S, ERP, and S, was delivered 10 msec after S, ERP. Diastole was scanned with a third extrastimulus (S,). S, was first introduced with a coupling interval equal to S,-S, and subsequently reduced in 10 msec steps until S, failed to provoke a ventricular response. The S,-S, interval was defined as the S, ERP, and S, was delivered 10 msec after this. A 2-second interval separated delivery of each train of atria1 and ventricular extrastimuli.
The left coronary artery was catheterized with a 5F or 6F catheter, and a bolus injection of 4 ml of either Hypaque-76, Iohexol-350, or Iohexol-140 was given in random order during a 2-minute repetitive stimulation of the protocol established above (Table I ). The limb lead II of the electrocardiogram, left ventricular pressure, and dP/dt were recorded (Model 28OOS, Gould Electronics, Cleveland, Ohio) (Fig. l) , before and for 2 minutes after injection of each agent. Tracings at 100 mm/set paper speed were recorded before injection and at 1 and 2 minutes after injection for QT interval measurements. Each agent was injected three times, and the period of injection was precisely recorded. A 4-minute resting period separated each test.
When sustained ventricular tachycardia or ventricular fibrillation occurred, defibrillation was attempted with a cardiac defibrillator (Mennen-Greatbatch Electronics, Clarence, N.Y.), set at 50 joules and applied directly to the heart. When defibrillation was required, further testing of the agents was suspended for at least 20 minutes. In eight dogs, the entire sequence of drug testing was repeated a second time. In two dogs, the sequence could not be completed due to unsuccessful defibrillation.
Tracings were analyzed for systolic blood pressure, left ventricular end-diastolic pressure, dP/dt, heart rate, QT interval, occurrence of single premature ventricular contractions, ventricular couplets, nonsustained ventricular tachycardia (defined as a sequence of at least three premature ventricular contractions that lasted no more than 30 seconds and spontaneously resolved), sustained ventricular tachycardia (defined as ventricular tachycardia lasting longer than 30 seconds or requiring treatment for resolution:), and ventricular fibrillation (defined as gross irregularity of the QRS complex and hemodynamic deterioration).
Hypothesis testing of frequency data was carried out by means of a clni square statistic'l 'Continuous variables were analyzed with BMDPSV statistical software (Biomedical Data Package, UC Press, Berkeley, Calif.) for mixed model unbalanced designs.'* A modified t test (Bonferroni) was used to assess specific differences from control values.'3 Data not normally distributed were analyzed with a Kruskal Wallis test. Results were considered significant when p < 0.05. hand as rapidly as possible, but because of viscosity differences, the injection duration differed for each agent. Mean infusion duration for Hypaque-76 was 3.2 + 1.3 seconds (*SD), for Iohexol-350 it was 3.2 + 1.3 seconds, and for Iohexol-140 it was 1.5 f 0.5 seconds (p = NS). QT interval differences were not significant at 1 and 2 minutes after injection. Hemodynamics parameters (systolic and end-diastolic pressure, dP/dt) were similar among all groups (Table II) . Temporal stability of each preparation was confirmed with a paired t test of pre-and post-protocol .basal pressures, dP/dt, and heart rate; no statistically significant changes were noted.
The incidence of evoked single and coupled premature ventricular contractions was not statistically different after infusion of any agent (Fig. 2j . Similarly, the incidence of nonsustained ventricular tachycardia was not significantly different-7 in 54 Hypaque-76 observations, 5 in 51 observations, p = NS. Sustained ventricular tachycardia occurred only after Hypaque-76 injections (5 episodes in 54 injections, p = 0.02), and degenerated into ventricular fibrillation each time.
Ventricular fibrillation occurred only after Hypaque-76 injections. While five episodes were a consequence of sustained ventricular tachycardia, two were primary events. Thus there were seven episodes of ventricular fibrillation after 54 Hypaque-76 injections (12.9 % ), and this was significantly greater than with the other agents 0, = 0.02). Cardioversion was successful in five of seven episodes.
DISCUSSION
Harmful effects of contrast agents are extensively described.'p3v 14-lg Suggested mechanisms that may induce these reactions include protein binding and inactivation of enzymatic function, deformation of erythrocyte morphology, complement activation, and direct cardiotoxicity.*, 14-17, 2o In addition, the presence of ethylenediamine tetraacetic acid (EDTA) and sodium citrate in some formulations may facilitate induction of arrhythmia.z*r22 Nonionic contrast media may alleviate some of these adverse reactions.23-26 They stimulate inducing mechanisms to a lesser degree, and several studies suggest that they induce fewer undesirable hemodynamic and electrocardiographic changes.27-34 Another long recognized potential inducer of adverse effects is hyperosmolarity.
Several reports6~23~27 have shown that low osmolarity contrast agents induce even less significant hemodynamic changes than standard media. Although their arrhythmogenicity has seldom been tested, some evidence34 suggests that nonionic, low oemolarity contrast media induce fewer arrhythmias than conventional agents. However, some studies7vh 1o,35 created controversy by suggesting that ionic and high osmolarity contrast media are safer. These conflicting studies differ predominantly in the method of contrast injection.
Studies that showed adverse effects of low osmolarity contrast agentsg,10,35 have routinely used high doses and prolonged infusions of contrast agents.
The current study is an attempt to simulate a more typical clinical situation by assessing the effects of rapid bolus hand injections. To potentiate the arrhythmogenicity of the contrast agents and to mimic a high-risk state,36 the heart was subjected to repeated ventricular stimulation. American Heart Journal this study offers an impetus for further evaluation of low osmolarity nonionic media in the setting of cardiac catheterization.
While some such agents are currently being used in Europe with reports of improved patient tolerance,37 studies addressing the quality of coronary and ventricular images when low osmolarity agents are used will be required.
